Jan 13, 2014 No Comments by

Curis, Inc.(NASDAQ:CRIS) provided an update noting that Phase 2 data of everolimus for Operable Nodular BCC (basal cell carcinoma) are due 1Q 2014. Their submission to the FDA regarding the partial clinical hold of CUDC-427 is due shortly. A Phase 2 trial of Debio 0932 is due to be to initiated in 2H 2014. Galena Biopharma (Nasdaq:GALE) announced it has […]

Daily News Read more

MDCO and NVS Adcom dates set. AEZS raising more cash. Approvals for BMY AZN GSK + updates for MSTX ALKS

Jan 09, 2014 No Comments by

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.46) announced that it has commenced another underwritten public offering of common shares and warrants, their third offering in just over five months. GW Pharmaceuticals plc (Nasdaq: GWPH $38.06) announced the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the NASDAQ Global Market. GW will issue 2,441,110 ADSs […]

Daily News Read more

ALXA reverse split. ALKS JNJ initiate Phase 3 schizophrenia. NYMX commences Phase 2 prostate cancer enrolment

Jun 13, 2012 No Comments by

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced a 1-for-10 reverse split of its common stock effective immediately. The number of common stock outstanding will correspondingly be reduced from approximately 119.6 million to approximately 12.0 million. Alkermes plc (NASDAQ: ALKS) announced that Janssen Research & Development, LLC has initiated a Phase 3 trial for a three-month formulation of INVEGA SUSTENNA(paliperidone palmitate), an injectable medicine […]

Daily News Read more

CHTP and ALKS halt further trials following disappointing trial data + OMER news

May 31, 2012 No Comments

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it failed to meet its primary endpoint in its Phase 2 trial of CH-4051 in patients with rheumatoid arthritis (RA). As a result it plans to discontinue development of CH-4051. Alkermes plc (NASDAQ: ALKS) said that it did not meet its “pre-specified criteria for advancing into Phase 3 clinical trials” […]

Read more

AMLN ALKS FDA Approval. INFI Phase 2 fail. BNVI to delist + RPRX RPTP TLON IMGN news

Jan 27, 2012 No Comments

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced the FDA  approved BYDUREON, the first once-weekly treatment for type 2 diabetes. BYDUREON will be available in pharmacies nationwide in February. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it is halting development of saridegib (IPI-926) in combination with gemcitabine for pancreatic cancer. Interim data […]

Read more

Upcoming PDUFA dates, Adcom meetings and clinical catalysts as of January 12 2012

Jan 12, 2012 No Comments

Some short and long term potential catalysts as of January 12, 2012 (share prices as at the close of trading Wednesday, January 11, 2012). See the links in the FDA Calendar for more details about each catalyst. The possible catalysts listed below represent both short and long opportunities. It is NOT a recommendation to take […]

Read more

Weekly Summary of key pharma events – week ended January 6 2012

Jan 07, 2012 No Comments

See individual posts made in the last week for more detail. PDUFA/NDA FILINGS/ADVISORY COMMITTEE NEWS AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) said that it intends to file its NDA for tivozanib during 2012 following full data release at ASCO this year. Cornerstone Therapeutics (NASDAQ: CRTX) – NDA for lixivaptan for the treatment of hyponatremia was filed on Dec. 29, […]

Read more

INFI pipeline update + ALKS and CLDX news

Jan 04, 2012 No Comments

Alkermes plc (NASDAQ: ALKS) today announced that it had initiated a Phase 2 trial of ALKS 5461 for major depressive disorder (MDD) following positive data from a Phase 1b trial. Data from the study are expected in the first half of calendar 2013. Celldex Therapeutics, Inc. (NASDAQ: CLDX)  initiated a Phase 2 trial of rindopepimut in combination with Avastin in […]

Read more

Merry Xmas – Summary of pharma events week ending 12/23/12

Dec 23, 2011 No Comments

A Merry Xmas to all readers of BioPharmCatalyst. Thank you all for your support over the past year and wish you all a relaxing break with friends and family! See individual posts made in the last week for more detail.   PDUFA/FDA RELATED EVENTS Santarus, Inc. (NASDAQ: SNTS) submitted its NDA for UCERIS for mild to […]

Read more

Upcoming Adcom meetings for CHTP & VVUS + ALKS FOLD RPTP TSRX news

Dec 19, 2011 No Comments

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) mentioned last month that the FDA indicated its intent to discuss the Northera NDA at a February 2012 meeting of its Cardiovascular and Renal Drugs Advisory Committee.  A tentative schedule of all 2012 meetings was released today with the above mentioned committee to meet on February 23. VIVUS, Inc. (NASDAQ: VVUS) […]

Read more

RPTP offering. NGSX files sNDA. EXEL data soon + PPHM ALKS

Sep 08, 2011 No Comments

Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced the pricing of its previously announced underwritten public offering of 10m shares of its common stock at a price to the public of $4 per share for net proceeds of approximately $37,250,000. NeurogesX, Inc. (Nasdaq:NGSX), today announced it submitted a supplemental new drug application (sNDA) to the FDA seeking […]

Read more